Satellos Bioscience Inc · TSX:MSCL
Satellos Bioscience — Life Science Investor Forum 2022
17 slides from Satellos Bioscience's conference presentation, Jun 23, 2022

Slide 1: Satellos Bioscience Inc. – Life Science Investor Forum
Life Science Investor Forum June 23, 2022 SATELLOS BIOSCIENCE INC. Rebuilding muscle from within TM 1

Slide 2: Legal Disclaimers
2 Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or perfor

Slide 3: Game-changing scientific discoveries with potential to revolutionize how muscle diseases are treated
3 Game-changing scientific discoveries with potential to revolutionize how muscle diseases are treated Muscle stem cell experts: Defining their role in driving muscle repair and regeneration ‘AHA’ discoveries: Duchenne muscular dystrophy is a disease of failed repair and regeneration Small mol

Slide 4: Satellos CSO and co-founder: Dr. Michael Rudnicki
4 Satellos CSO and co-founder: Scientific giant in muscle stem cell driven repair & regeneration Dr. Michael Rudnicki 2000 2009 2013 2016 Over 235 publications with h-factor of 103 2007 2012 2015 2019 4

Slide 5: Foundational discoveries
5 Foundational discoveries: Groundbreaking insights into regeneration in health and disease Muscle Stem Cells Defined Regeration Failure Tendon Pax7+/Myf5- Dividing stem cell Healthy Repair and Regeneration X Dividing stem cell Muscle stem cell Muscle progenitor cells (maintenance) (regeneration) 5

Slide 6: Duchenne: A fatal disease with no known cure
6 Duchenne: A fatal disease with no known cure The patient journey Treatment approaches Dystrophin Gene 1 in 4,000 boys correction X-linked gene mutation Anti- Heart Dystrophin protein not produced inflammation function Target fibers not stem cells Anti- Energy/ fibrosis Mitochondria Muscle pr

Slide 7: "AHA" Discovery: Muscle regeneration fails without polarity
7 “AHA” Discovery: Muscle regeneration fails when s.c.’s don’t establish ‘polarity’ Regeneration Regeneration Healthy Polarity Occurs Duchenne Polarity Deficit Muscle fiber Muscle fiber 210-12 divisions Progenitor N Stem cell S Stem cell Stem cell Basal lamina Dmd = dystrophin Basal lamina What evid

Slide 8: Evidence in patients
8 Evidence in patients: Duchenne study** cites polarity as potential disease modifier Some patients keep walking: Why? Nationwide study summary: No steroid treatment Steroid treatment Largest study ever in Duchenne patients Identified mutation affecting Boys with mutation Boys with mutation musc

Slide 9: Satellos approach: correct polarity with drug
9 Satellos approach: Correct polarity with drug to restore muscle regeneration Problem: Solution: Impaired polarity in Duchenne Correct polarity in Duchenne Oversupply of X Not enough muscle Sufficient muscle Sufficient muscle muscle stem cells progenitor cells stem cells progenitor cells We have ge

Slide 10: Proof of Concept: Satellos treatment improves outcomes in Duchenne model
10 Proof of Concept (POC): Satellos treatment improves outcomes in Duchenne model Restoring polarity: Impaired polarity in Mdx Satellos Drug Corrects repair and regeneration Mdx Mouse Leads to higher quality, more functional muscle X Satellos progress: Identified multiple regulatory pathways 4

Slide 11: Satellos on track
11 Satellos on track: Delivering on key performance indicators from RTO Q3/2021 Q4/2021 Q1/2022 Q2/2022 Q3/2022 Q4/2022 RTO 08/13/2021 Status: Multiple drug series identified and prioritized Design / advance drug candidates and file IP Hundreds of compounds synthesized and assessed IP filings

Slide 12: Vision for continuous value build over next 24 months
12 Vision for continuous value build over next 24 months Q2/22 Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Duchenne program Delivered by Q2/24 Follow-on indication IND/CTA application approved in Delivered by Q2/24 USA & Canada 2nd drug program Follow-on indication selected Delivered by Q2/2

Slide 13: Significant value in muscle
13 Significant value in muscle: Attractive capitalizations on early data and room for growth Phase 3 / Commercial 36 – 60 months US$1.9BN US$5.5BN US$175M Phase 1 - 2 Trials 18 – 36 months US$67M US$300M US$260M US$590M Pre-IND/IND 12 – 18 months US$12M Development Stages Timeline Goals PEER COMPANI

Slide 14: Board and Science Advisory Board
14 Board Geoffrey Mackay Adam Mostafa Rima Al-awar, PhD William McVicar, PhD William Jarosz, JD Frank Gleeson, MBA Chair — Board of Directors Chair – Audit Committee Board Member Board Member & Advisor CEO – AmpB Technologies Inc. Co-Founder & CEO Founder and CEO - CFO - X4 Head – Drug Disc.,

Slide 15: Broad Intellectual Property
15 Issued SATELLOS Multiple issued patents related to polarity modulator Wnt7a and its method of use in treating degenerative muscle diseases Broad Intellectual In process/pending Property Multiple mechanistic patent filings surrounding the regulation of polarity via modulating specific pathways

Slide 16: Background and Cap Table
16 SATELLOS: Background and Cap Table BACKGROUND CAPITAL TABLE Founded 04/2018 by repeat Common Shares 32,995,548 biotechnology players Warrants 2,162,762 Raised $15m to-date through Stock options 2,847,252 HMW investors Fully Diluted 38,005,562 Completed RTO and listing on TSX.V on Aug 13, 20

Slide 17: Thank You!
THANK YOU! Contact Information: 65 Front Street East, Suite 201 | Toronto, ON M5E 1B5 17 647-660-1780 | info@satellos.com | TSX: MSCL.V | PINK: MSCLF
Source: Internet Archive copy of satellos.com
More decks from Satellos Bioscience Inc
Corporate Update (November 2026)17 slides · Nov 6, 2026
Corporate Update (July 2026)14 slides · Jul 8, 2026
2026 Bloom Burton & Co. Healthcare Investor Conference23 slides · April 2026
Technical Presentation (February 2026)52 slides · Feb 24, 2026
Investor Presentation (February 2026)21 slides · February 2026
Investor Presentation (October 2025)19 slides · October 2025